Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.

DeTACT Group Photo

MORU has been working over the last 10 years on the development of triple artemisinin-based combination therapies (TACTs), combining two partner drugs instead of the conventional single partner drug in ACTs. This new combination therapy is needed to tackle the increasing problem of artemisinin and ACT partner drug resistance, which jeopardizes effective treatment of Plasmodium falciparum malaria. Artemisinin resistance started in the Greater Mekong Subregion (GMS) around 20 years ago, but has more recently emerged in several Sub-Saharan African countries.

Participants shared findings across all DeTACT project work packages, including drug development, clinical trials in Asia and Africa, mathematical modeling, bioethics, market positioning, communication and engagement, and individual patient data meta-analysis (IPD-MA).

The two TACTs developed under the project – artemether-lumefantrine plus amodiaquine (AL+AQ) and artesunate-mefloquine plus piperaquine (ASMQ+PPQ) – were evaluated in a randomized, placebo-controlled, partially-blinded clinical trial involving nearly 2,700 patients with uncomplicated P. falciparum malaria. Both combinations demonstrated excellent efficacy and safety, comparable to current ACTs. Notably, AL+AQ was more efficacious than AL in Cambodia, where nearly all infections were artemisinin resistant.

Mathematical modeling underscored the urgent need to deploy TACTs as soon as possible to delay antimalarial drug resistance, reduce treatment failures, and increase the likelihood of malaria elimination across diverse epidemiological settings. Complementary bioethical and market positioning studies identified potential implementation challenges and proposed practical solutions. Engagement efforts with national malaria control programs in 20 African countries and other stakeholders have significantly raised awareness about TACTs and their potential role. The reports from the IPD-MA will be submitted as part of the regulatory dossier for ALAQ registration and will be used to support TACT implementation and policy development.

The meeting also featured presentations on the DeTACT follow-up initiative: the ALAQ Fixed-Dose Triple ACT (FD-TACT) project – a collaboration between Fosun Pharma, MMV, Marubeni, and MORU – funded by the Global Health Innovative Technology (GHIT) Fund. This pivotal clinical trial to be conducted across five countries in Africa and Asia will confirm the efficacy, safety, and tolerability of a new fixed-dose combination of ALAQ developed by Fosun Pharma. Regulatory submissions incorporating outputs from the IPD-MA, national registrations, commercialization, ALAQ deployment roadmaps, and post-marketing pharmacovigilance will follow.

With successful trial outcomes and regulatory approval, ALAQ FDC will soon become a valuable new tool in the global fight against malaria.

- Text by Arjen Dondorp, Mehul Dhorda and Chanaki Amaratunga.

 Photo courtesy of DeTACT.

Similar stories

Salum Mshamu named a 2026 TIME Trailblazer

Congratulations to Salum Mshamu on being selected as one of TIME’s inaugural 2026 Trailblazers: Designing and Making the Future. A University of Oxford DPhil student, Salum was recognised for his contribution to research showing how improved housing design can reduce malaria and other childhood illnesses.

Oxford, WHO and partners announce next-generation AI initiative to detect, assess and respond to pandemics

The University of Oxford has been awarded €8 million through the European Union’s Horizon Europe programme to coordinate the development of the Pandemics AI Observatory (PANDAI). Led by the University in partnership with the World Health Organization and an international consortium of leading research, public health and technology partners, the three-year project will develop and deploy advanced artificial intelligence (AI) models to transform the detection, assessment, prediction and response to global infectious disease threats.

Behind the Title: Becoming an Oxford Professor (at NDM): Featuring Professor Direk Limmathurotsakul

The Behind the Title: Becoming an Oxford Professor (at NDM) series highlights the diverse journeys of our professors and the many paths that lead to academic leadership. By sharing their journeys we aim to showcase the breadth of backgrounds, disciplines, and experiences represented across the Department, demonstrating that there is no single route to becoming a professor at Oxford.

MODRA Cohort 1: Where they are now and what comes next?

Eighteen months after joining MODRA, our first fellows are leading projects, winning grants, and building new collaborations across the region. Upon completion of the MODRA programme and moving move into the next stage of their careers, here’s a look at how our fellows are turning learning into lasting impact.

Professor Direk Limmathurotsakul awarded 2026 UNESCO-Carlos J. Finlay Prize for Microbiology

Professor Direk Limmathurotsakul has received the 2026 UNESCO-Carlos J. Finlay Prize for Microbiology. The Prize recognises his contributions to microbiology, particularly his work on melioidosis, antimicrobial-resistant (AMR) infections and turning local data into public health action.

MORU research highlighted during The Princess Royal’s visit to Mahidol University

A film featuring melioidosis survivors and a tour of a MORU malaria laboratory highlighted how patient-centred research and laboratory capacity contribute to regional health security.

Similar stories

Salum Mshamu named a 2026 TIME Trailblazer

Congratulations to Salum Mshamu on being selected as one of TIME’s inaugural 2026 Trailblazers: Designing and Making the Future. A University of Oxford DPhil student, Salum was recognised for his contribution to research showing how improved housing design can reduce malaria and other childhood illnesses.

Oxford, WHO and partners announce next-generation AI initiative to detect, assess and respond to pandemics

The University of Oxford has been awarded €8 million through the European Union’s Horizon Europe programme to coordinate the development of the Pandemics AI Observatory (PANDAI). Led by the University in partnership with the World Health Organization and an international consortium of leading research, public health and technology partners, the three-year project will develop and deploy advanced artificial intelligence (AI) models to transform the detection, assessment, prediction and response to global infectious disease threats.

Behind the Title: Becoming an Oxford Professor (at NDM): Featuring Professor Direk Limmathurotsakul

The Behind the Title: Becoming an Oxford Professor (at NDM) series highlights the diverse journeys of our professors and the many paths that lead to academic leadership. By sharing their journeys we aim to showcase the breadth of backgrounds, disciplines, and experiences represented across the Department, demonstrating that there is no single route to becoming a professor at Oxford.

MODRA Cohort 1: Where they are now and what comes next?

Eighteen months after joining MODRA, our first fellows are leading projects, winning grants, and building new collaborations across the region. Upon completion of the MODRA programme and moving move into the next stage of their careers, here’s a look at how our fellows are turning learning into lasting impact.

Professor Direk Limmathurotsakul awarded 2026 UNESCO-Carlos J. Finlay Prize for Microbiology

Professor Direk Limmathurotsakul has received the 2026 UNESCO-Carlos J. Finlay Prize for Microbiology. The Prize recognises his contributions to microbiology, particularly his work on melioidosis, antimicrobial-resistant (AMR) infections and turning local data into public health action.

MORU research highlighted during The Princess Royal’s visit to Mahidol University

A film featuring melioidosis survivors and a tour of a MORU malaria laboratory highlighted how patient-centred research and laboratory capacity contribute to regional health security.